' 
SCIENTIFIC SCORE
Moderately Effective
Based on 4 Researches
8.5
USERS' SCORE
Good
Based on 8 Reviews
8.9
Supplement Facts
Serving Size: 2 Capsules
Amount Per Serving
%DV
Total Carbohydrate
<1 g
<1%†
Calcium (from calcium magnesium phytate)
131 mg
10%
Phosphorus (from calcium magnesium phytate)
192 mg
15%
Magnesium (from calcium magnesium phytate)
40 mg
10%
IP-6 (inositol hexaphosphate) (from calcium magnesium phytate)
800 mg
**
Inositol
220 mg
**
Top Medical Research Studies
9
IP6 potentially prevents prostate cancer
Stage-Specific Effect of Inositol Hexaphosphate on Cancer Stem Cell Pool during Growth and Progression of Prostate Tumorigenesis in TRAMP Model.
Direct investigation of IP6 effects
We evaluated how inositol hexaphosphate (IP6), a natural compound found in various foods, influences the growth and development of prostate cancer in a special group of mice known as TRAMP. The study involved feeding these male mice either regular water or water containing 2% IP6 at different stages of their growth – starting at 4, 12, 20, and 30 weeks of age – for a period of about 8 to 15 weeks.
Pathological evaluations at the end of the study revealed some encouraging results. The IP6 treatment seemed to halt tumor progression earlier on, and it significantly reduced the incidence of more severe forms of the disease by around 55% to 70%. This finding suggests that IP6 could have a crucial role in preventing prostate cancer from advancing in severity.
Furthermore, we explored the effects of IP6 on cancer stem cells (CSCs), a small group of cells within tumors that can drive cancer growth. The results indicated that IP6 might help in reducing these CSCs in prostate tumors. In laboratory tests, we also found that IP6 treatment dramatically decreased the number of floating prostate cancer stem cell clusters by approximately 90%.
Overall, these findings suggest that IP6 holds significant promise as a preventive measure against prostate cancer, particularly at earlier stages of the disease.
Pathological evaluations at the end of the study revealed some encouraging results. The IP6 treatment seemed to halt tumor progression earlier on, and it significantly reduced the incidence of more severe forms of the disease by around 55% to 70%. This finding suggests that IP6 could have a crucial role in preventing prostate cancer from advancing in severity.
Furthermore, we explored the effects of IP6 on cancer stem cells (CSCs), a small group of cells within tumors that can drive cancer growth. The results indicated that IP6 might help in reducing these CSCs in prostate tumors. In laboratory tests, we also found that IP6 treatment dramatically decreased the number of floating prostate cancer stem cell clusters by approximately 90%.
Overall, these findings suggest that IP6 holds significant promise as a preventive measure against prostate cancer, particularly at earlier stages of the disease.
Read More
9
Inositol's role in prostate cancer
IMPA1-derived inositol maintains stemness in castration-resistant prostate cancer via IMPDH2 activation.
High relevance to prostate cancer
In our exploration of the role of inositol in prostate cancer, we found that a specific form of inositol derived from the IMPA1 enzyme plays a crucial role in the development and maintenance of prostate cancer stem cells (PCSCs). These PCSCs are important because they contribute to the progression of castration-resistant prostate cancer (CRPC), particularly after patients undergo androgen ablation therapy (ABT).
We observed that when the IMPA1 gene was conditionally knocked out in the prostate of a mouse model, the number and characteristics of these cancer stem cells were significantly reduced. This finding suggests that inositol not only supports the survival of these cells but also contributes to the aggressive nature of CRPC.
Furthermore, inositol interacts with another protein named IMPDH2 to create guanylate nucleotides, necessary for the survival of PCSCs, demonstrating a complex metabolic relationship that deepens our understanding of this cancer's resistance to treatment. The study also highlighted that the INMPA1/inositol/IMPDH2 pathway is often upregulated in human prostate cancer and that this overexpression correlates with poorer survival rates.
Targeting this pathway could be a promising strategy. Our findings show that disrupting the IMPA1/inositol/IMPDH2 axis can reverse CRPC and help overcome resistance to ABT in various experimental models.
We observed that when the IMPA1 gene was conditionally knocked out in the prostate of a mouse model, the number and characteristics of these cancer stem cells were significantly reduced. This finding suggests that inositol not only supports the survival of these cells but also contributes to the aggressive nature of CRPC.
Furthermore, inositol interacts with another protein named IMPDH2 to create guanylate nucleotides, necessary for the survival of PCSCs, demonstrating a complex metabolic relationship that deepens our understanding of this cancer's resistance to treatment. The study also highlighted that the INMPA1/inositol/IMPDH2 pathway is often upregulated in human prostate cancer and that this overexpression correlates with poorer survival rates.
Targeting this pathway could be a promising strategy. Our findings show that disrupting the IMPA1/inositol/IMPDH2 axis can reverse CRPC and help overcome resistance to ABT in various experimental models.
Read More
8
Myo-inositol reduces prostate cancer viability
Proteomic Analysis of Anticancer Effect of Myo-inositol in Human Prostate Cancer (DU-145) Cell Line.
Direct investigation of Myo-inositol effects
We examined how Myo-inositol, a natural compound, influences prostate cancer cells, specifically the DU-145 cell line. The study aimed to evaluate its potential as a treatment by determining how it affects cell survival and protein expression.
To do this, we treated the DU-145 cells with varying doses of Myo-inositol and assessed cell viability using a method called the trypan blue exclusion assay. Our findings showcased that Myo-inositol significantly decreased cell viability, with an IC50 value of 0.06 mg/ml, indicating that it could hinder cancer cell growth effectively.
Moreover, we explored the changes in protein expression brought about by Myo-inositol treatment. Our proteomic analysis revealed notable differences in the proteins expressed in treated cells compared to untreated ones. There were key alterations in proteins associated with preventing cell death and managing stress, suggesting that Myo-inositol might engage in important cancer-fighting pathways.
Overall, our results suggest that Myo-inositol exhibits considerable anticancer effects on prostate cancer cells. Although it shows promise as a supplementary treatment, we stress the need for further research to unveil the precise mechanisms of action and explore its potential in combination therapies for advanced prostate cancer.
To do this, we treated the DU-145 cells with varying doses of Myo-inositol and assessed cell viability using a method called the trypan blue exclusion assay. Our findings showcased that Myo-inositol significantly decreased cell viability, with an IC50 value of 0.06 mg/ml, indicating that it could hinder cancer cell growth effectively.
Moreover, we explored the changes in protein expression brought about by Myo-inositol treatment. Our proteomic analysis revealed notable differences in the proteins expressed in treated cells compared to untreated ones. There were key alterations in proteins associated with preventing cell death and managing stress, suggesting that Myo-inositol might engage in important cancer-fighting pathways.
Overall, our results suggest that Myo-inositol exhibits considerable anticancer effects on prostate cancer cells. Although it shows promise as a supplementary treatment, we stress the need for further research to unveil the precise mechanisms of action and explore its potential in combination therapies for advanced prostate cancer.
Read More
Most Useful Reviews
9.5
Effective treatment
Cancer free. I take IP6 with finasteride (hormone) to maintain my PSA at 1; I have prostate cancer—it works for me and has for the past nine years.
Read More
10
Prevents cancer recurrence
After treatment for prostate cancer, I was advised to use this product every morning. Fifteen years later, I’ve had no recurrence of prostate cancer. My wife had breast pain that disappeared after taking this product for a week. I'm thoroughly convinced of its efficacy; the cost is minimal considering how long it lasts!
Read More
9.5
Prevents infection
This is an excellent supplement. My boyfriend, who has aggressive stage IV prostate cancer and is undergoing chemotherapy, initially suffered from mouth sores and low blood counts. After starting on IP-6, his next treatment was much better, with his blood counts remaining stable and no infections. His PSA levels dropped significantly as well. I'm ordering the powdered form now for convenience.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 4 Researches
8.5
- All Researches
9
Inositol's role in prostate cancer
IMPA1-derived inositol maintains stemness in castration-resistant prostate cancer via IMPDH2 activation.
High relevance to prostate cancer
In our exploration of the role of inositol in prostate cancer, we found that a specific form of inositol derived from the IMPA1 enzyme plays a crucial role in the development and maintenance of prostate cancer stem cells (PCSCs). These PCSCs are important because they contribute to the progression of castration-resistant prostate cancer (CRPC), particularly after patients undergo androgen ablation therapy (ABT).
We observed that when the IMPA1 gene was conditionally knocked out in the prostate of a mouse model, the number and characteristics of these cancer stem cells were significantly reduced. This finding suggests that inositol not only supports the survival of these cells but also contributes to the aggressive nature of CRPC.
Furthermore, inositol interacts with another protein named IMPDH2 to create guanylate nucleotides, necessary for the survival of PCSCs, demonstrating a complex metabolic relationship that deepens our understanding of this cancer's resistance to treatment. The study also highlighted that the INMPA1/inositol/IMPDH2 pathway is often upregulated in human prostate cancer and that this overexpression correlates with poorer survival rates.
Targeting this pathway could be a promising strategy. Our findings show that disrupting the IMPA1/inositol/IMPDH2 axis can reverse CRPC and help overcome resistance to ABT in various experimental models.
We observed that when the IMPA1 gene was conditionally knocked out in the prostate of a mouse model, the number and characteristics of these cancer stem cells were significantly reduced. This finding suggests that inositol not only supports the survival of these cells but also contributes to the aggressive nature of CRPC.
Furthermore, inositol interacts with another protein named IMPDH2 to create guanylate nucleotides, necessary for the survival of PCSCs, demonstrating a complex metabolic relationship that deepens our understanding of this cancer's resistance to treatment. The study also highlighted that the INMPA1/inositol/IMPDH2 pathway is often upregulated in human prostate cancer and that this overexpression correlates with poorer survival rates.
Targeting this pathway could be a promising strategy. Our findings show that disrupting the IMPA1/inositol/IMPDH2 axis can reverse CRPC and help overcome resistance to ABT in various experimental models.
Read More
9
IP6 potentially prevents prostate cancer
Stage-Specific Effect of Inositol Hexaphosphate on Cancer Stem Cell Pool during Growth and Progression of Prostate Tumorigenesis in TRAMP Model.
Direct investigation of IP6 effects
We evaluated how inositol hexaphosphate (IP6), a natural compound found in various foods, influences the growth and development of prostate cancer in a special group of mice known as TRAMP. The study involved feeding these male mice either regular water or water containing 2% IP6 at different stages of their growth – starting at 4, 12, 20, and 30 weeks of age – for a period of about 8 to 15 weeks.
Pathological evaluations at the end of the study revealed some encouraging results. The IP6 treatment seemed to halt tumor progression earlier on, and it significantly reduced the incidence of more severe forms of the disease by around 55% to 70%. This finding suggests that IP6 could have a crucial role in preventing prostate cancer from advancing in severity.
Furthermore, we explored the effects of IP6 on cancer stem cells (CSCs), a small group of cells within tumors that can drive cancer growth. The results indicated that IP6 might help in reducing these CSCs in prostate tumors. In laboratory tests, we also found that IP6 treatment dramatically decreased the number of floating prostate cancer stem cell clusters by approximately 90%.
Overall, these findings suggest that IP6 holds significant promise as a preventive measure against prostate cancer, particularly at earlier stages of the disease.
Pathological evaluations at the end of the study revealed some encouraging results. The IP6 treatment seemed to halt tumor progression earlier on, and it significantly reduced the incidence of more severe forms of the disease by around 55% to 70%. This finding suggests that IP6 could have a crucial role in preventing prostate cancer from advancing in severity.
Furthermore, we explored the effects of IP6 on cancer stem cells (CSCs), a small group of cells within tumors that can drive cancer growth. The results indicated that IP6 might help in reducing these CSCs in prostate tumors. In laboratory tests, we also found that IP6 treatment dramatically decreased the number of floating prostate cancer stem cell clusters by approximately 90%.
Overall, these findings suggest that IP6 holds significant promise as a preventive measure against prostate cancer, particularly at earlier stages of the disease.
Read More
8
Myo-inositol reduces prostate cancer viability
Proteomic Analysis of Anticancer Effect of Myo-inositol in Human Prostate Cancer (DU-145) Cell Line.
Direct investigation of Myo-inositol effects
We examined how Myo-inositol, a natural compound, influences prostate cancer cells, specifically the DU-145 cell line. The study aimed to evaluate its potential as a treatment by determining how it affects cell survival and protein expression.
To do this, we treated the DU-145 cells with varying doses of Myo-inositol and assessed cell viability using a method called the trypan blue exclusion assay. Our findings showcased that Myo-inositol significantly decreased cell viability, with an IC50 value of 0.06 mg/ml, indicating that it could hinder cancer cell growth effectively.
Moreover, we explored the changes in protein expression brought about by Myo-inositol treatment. Our proteomic analysis revealed notable differences in the proteins expressed in treated cells compared to untreated ones. There were key alterations in proteins associated with preventing cell death and managing stress, suggesting that Myo-inositol might engage in important cancer-fighting pathways.
Overall, our results suggest that Myo-inositol exhibits considerable anticancer effects on prostate cancer cells. Although it shows promise as a supplementary treatment, we stress the need for further research to unveil the precise mechanisms of action and explore its potential in combination therapies for advanced prostate cancer.
To do this, we treated the DU-145 cells with varying doses of Myo-inositol and assessed cell viability using a method called the trypan blue exclusion assay. Our findings showcased that Myo-inositol significantly decreased cell viability, with an IC50 value of 0.06 mg/ml, indicating that it could hinder cancer cell growth effectively.
Moreover, we explored the changes in protein expression brought about by Myo-inositol treatment. Our proteomic analysis revealed notable differences in the proteins expressed in treated cells compared to untreated ones. There were key alterations in proteins associated with preventing cell death and managing stress, suggesting that Myo-inositol might engage in important cancer-fighting pathways.
Overall, our results suggest that Myo-inositol exhibits considerable anticancer effects on prostate cancer cells. Although it shows promise as a supplementary treatment, we stress the need for further research to unveil the precise mechanisms of action and explore its potential in combination therapies for advanced prostate cancer.
Read More
8
Inositol's potential in radiation therapy
Decreasing undesirable absorbed radiation to the intestine after administration of radium-223 dichloride for treatment of bone metastases.
Limited direct cancer outcome assessment
We examined the potential of a compound called myo-inositol-hexakisphosphate (Zn-InsP6) to lessen the side effects of a treatment known as radium-223 dichloride for prostate cancer patients. This treatment is commonly used for those suffering from bone metastases, but there's a concern that some of the emitted radiation can be absorbed into the bloodstream from the intestines, leading to unwanted exposure.
In our investigation, we found that Zn-InsP6 can effectively bind to radium. This binding may reduce the absorption of radium into the body after it is expelled into the intestines through waste. Through experiments conducted on mice, we discovered that those treated with Zn-InsP6 had significantly lower levels of radioactivity in their bones compared to the control group, suggesting that the compound does indeed limit radium absorption.
However, it is important to note that our study did not directly assess the impact of inositol on prostate cancer outcomes. While there's potential for Zn-InsP6 to minimize radiation exposure and its side effects, we did not evaluate any improvements in cancer treatment outcomes directly attributable to inositol. Thus, while it's a promising area of research, we need further studies to draw solid conclusions about its effectiveness in prostate cancer management.
In our investigation, we found that Zn-InsP6 can effectively bind to radium. This binding may reduce the absorption of radium into the body after it is expelled into the intestines through waste. Through experiments conducted on mice, we discovered that those treated with Zn-InsP6 had significantly lower levels of radioactivity in their bones compared to the control group, suggesting that the compound does indeed limit radium absorption.
However, it is important to note that our study did not directly assess the impact of inositol on prostate cancer outcomes. While there's potential for Zn-InsP6 to minimize radiation exposure and its side effects, we did not evaluate any improvements in cancer treatment outcomes directly attributable to inositol. Thus, while it's a promising area of research, we need further studies to draw solid conclusions about its effectiveness in prostate cancer management.
Read More
User Reviews
USERS' SCORE
Good
Based on 8 Reviews
8.9
- All Reviews
- Positive Reviews
- Negative Reviews
9.5
Effective treatment
Cancer free. I take IP6 with finasteride (hormone) to maintain my PSA at 1; I have prostate cancer—it works for me and has for the past nine years.
10
Prevents cancer recurrence
After treatment for prostate cancer, I was advised to use this product every morning. Fifteen years later, I’ve had no recurrence of prostate cancer. My wife had breast pain that disappeared after taking this product for a week. I'm thoroughly convinced of its efficacy; the cost is minimal considering how long it lasts!
Read More
9.5
Prevents infection
This is an excellent supplement. My boyfriend, who has aggressive stage IV prostate cancer and is undergoing chemotherapy, initially suffered from mouth sores and low blood counts. After starting on IP-6, his next treatment was much better, with his blood counts remaining stable and no infections. His PSA levels dropped significantly as well. I'm ordering the powdered form now for convenience.
Read More
9.5
Preventive aid
This item is rather expensive. I believe it should assist individuals with cancer. At present, I am taking this as a preventive measure.
9.5
Preventive aid
This item is rather expensive. I believe it should assist individuals with cancer. At present, I am taking this as a preventive measure.
